Literature DB >> 24412650

Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing.

Nadine Laguette1, Christelle Brégnard2, Pauline Hue2, Jihane Basbous3, Ahmad Yatim2, Marion Larroque3, Frank Kirchhoff4, Angelos Constantinou3, Bijan Sobhian2, Monsef Benkirane5.   

Abstract

The HIV auxiliary protein Vpr potently blocks the cell cycle at the G2/M transition. Here, we show that G2/M arrest results from untimely activation of the structure-specific endonuclease (SSE) regulator SLX4 complex (SLX4com) by Vpr, a process that requires VPRBP-DDB1-CUL4 E3-ligase complex. Direct interaction of Vpr with SLX4 induced the recruitment of VPRBP and kinase-active PLK1, enhancing the cleavage of DNA by SLX4-associated MUS81-EME1 endonucleases. G2/M arrest-deficient Vpr alleles failed to interact with SLX4 or to induce recruitment of MUS81 and PLK1. Furthermore, knockdown of SLX4, MUS81, or EME1 inhibited Vpr-induced G2/M arrest. In addition, we show that the SLX4com is involved in suppressing spontaneous and HIV-1-mediated induction of type 1 interferon and establishment of antiviral responses. Thus, our work not only reveals the identity of the cellular factors required for Vpr-mediated G2/M arrest but also identifies the SLX4com as a regulator of innate immunity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24412650     DOI: 10.1016/j.cell.2013.12.011

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  123 in total

1.  HIV-1 Vpr protein activates the NF-κB pathway to promote G2/M cell cycle arrest.

Authors:  Zhibin Liang; Ruikang Liu; Yongquan Lin; Chen Liang; Juan Tan; Wentao Qiao
Journal:  Virol Sin       Date:  2015-12-14       Impact factor: 4.327

2.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

3.  Vpr Targets TET2 for Degradation by CRL4VprBP E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication.

Authors:  Lei Lv; Qi Wang; Yanping Xu; Li-Chung Tsao; Tadashi Nakagawa; Haitao Guo; Lishan Su; Yue Xiong
Journal:  Mol Cell       Date:  2018-06-07       Impact factor: 17.970

Review 4.  Innate immunity against HIV-1 infection.

Authors:  Marcus Altfeld; Michael Gale
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

5.  Understanding the molecular manipulation of DCAF1 by the lentiviral accessory proteins Vpr and Vpx.

Authors:  Patrick A Cassiday; Ana Beatriz DePaula-Silva; Jeffrey Chumley; Jeffrey Ward; Edward Barker; Vicente Planelles
Journal:  Virology       Date:  2014-12-11       Impact factor: 3.616

Review 6.  Subversion of Cell Cycle Regulatory Mechanisms by HIV.

Authors:  Andrew P Rice; Jason T Kimata
Journal:  Cell Host Microbe       Date:  2015-06-10       Impact factor: 21.023

7.  HIV-1 Vpr Protein Enhances Proteasomal Degradation of MCM10 DNA Replication Factor through the Cul4-DDB1[VprBP] E3 Ubiquitin Ligase to Induce G2/M Cell Cycle Arrest.

Authors:  Bizhan Romani; Nima Shaykh Baygloo; Mohammad Reza Aghasadeghi; Elham Allahbakhshi
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

8.  The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction.

Authors:  Ying Wu; Xiaohong Zhou; Christopher O Barnes; Maria DeLucia; Aina E Cohen; Angela M Gronenborn; Jinwoo Ahn; Guillermo Calero
Journal:  Nat Struct Mol Biol       Date:  2016-08-29       Impact factor: 15.369

9.  HIV-1 Vpr hijacks EDD-DYRK2-DDB1DCAF1 to disrupt centrosome homeostasis.

Authors:  Delowar Hossain; Jérémy A Ferreira Barbosa; Éric A Cohen; William Y Tsang
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

10.  Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING.

Authors:  Maud Trotard; Nikolaos Tsopoulidis; Nadine Tibroni; Joschka Willemsen; Marco Binder; Alessia Ruggieri; Oliver T Fackler
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.